Bristol Will Use One Distributor To Ensure Patient Access For Orencia Launch
Executive Summary
Bristol-Myers Squibb is launching its rheumatoid arthritis treatment Orencia (abatacept) through a sole distributor to ensure patient access while the firm works to expand its manufacturing capacity
You may also be interested in...
Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said
Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said
Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now
Professional education efforts will be the centerpiece of Bristol-Myers Squibb's late-February launch of the rheumatoid arthritis treatment Orencia (abatacept) under the company's voluntary direct-to-consumer advertising moratorium for new products